Pyxis Oncology (PYXS) Total Non-Current Liabilities (2020 - 2024)
Pyxis Oncology (PYXS) posted quarterly Total Non-Current Liabilities of $41.6 million for Q3 2024, down 14.6% year-over-year from $48.7 million in Q4 2023, and up 7.87% quarter-over-quarter from $38.6 million in Q2 2024.
Pyxis Oncology (PYXS) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Pyxis Oncology (PYXS) has reported Total Non-Current Liabilities for 5 consecutive years, with $41.6 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Total Non-Current Liabilities fell 14.6% year-over-year to $41.6 million; the TTM figure through Sep 2024 stood at $41.6 million (down 14.6% YoY), while the FY2023 annual figure was $48.0 million, down 5.01% from the prior year.
- Total Non-Current Liabilities grew to $41.6 million in Q3 2024 per PYXS's latest filing, from $38.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $50.6 million in Q4 2022 and bottomed at -$3.4 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $29.6 million across 5 years, with a median of $32.9 million in 2022.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 664.32% — and 2024, when it declined 14.6%.
- Pyxis Oncology's Total Non-Current Liabilities stood at $3.9 million in 2020, then soared by 385.42% to $18.7 million in 2021, then soared by 170.23% to $50.6 million in 2022, then slipped by 5.01% to $48.0 million in 2023, then declined by 13.31% to $41.6 million in 2024.
- Business Quant data shows PYXS's Total Non-Current Liabilities at $41.6 million in Q3 2024, $38.6 million in Q2 2024, and $36.1 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 41.63 Mn |
| Jun 30, 2024 | 38.60 Mn |
| Mar 31, 2024 | 36.06 Mn |
| Dec 31, 2023 | 48.02 Mn |
| Sep 30, 2023 | 48.75 Mn |
| Jun 30, 2023 | 29.96 Mn |
| Dec 31, 2022 | 50.56 Mn |
| Sep 30, 2022 | 35.15 Mn |
| Jun 30, 2022 | 30.60 Mn |
| Mar 31, 2022 | 19.19 Mn |
| Dec 31, 2021 | 18.71 Mn |
| Sep 30, 2021 | 16.84 Mn |
| Mar 31, 2021 | -3.40 Mn |
| Dec 31, 2020 | 3.85 Mn |